LEARNING · INGREDIENT SCIENCE
CL-K1®
From fungal strain discovery to a standardized bioactive ingredient platform for metabolic health.
WHAT IS CL-K1®
CL-K1® stands for Ceriporia lacerata-K1, a natural-origin bioactive ingredient developed by Longrunn Medical through microbial strain research and fungal fermentation technology.
It originated from the study of Ceriporia lacerata, a fungal strain first identified during research on bioactive compounds from medicinal mushrooms. Through continued strain improvement, cultivation optimization, and standardization, CL-K1® has developed into a research-based ingredient platform for metabolic health.
CL-K1® is best understood as a multi-target cellular nutrition platform focused on glucose metabolism, insulin response, liver-related metabolic health, oxidative stress, inflammatory balance, and cellular energy regulation.
A Strain Development Journey Since 2005
Each generation improved cultivation efiiciency, biological stability and industrial application potential
01
Published Research
Explore peer-reviewed studies and publicly available scientific literature related to Ceriporia lacerata CL-K1.
02
Current Studies
Follow the company's ongoing research, experimental progress, and scientific evidence development.
03
Certifications & IP
Review certifications, approvals, and intellectual property progress across Korea, Singapore, Malaysia, and other markets.
A Strain Development Journey Since 2005
Each generation improved cultivation efiiciency, biological stability and industrial application potential
01
DISCOVERY
Ceriporia lacerata
The natural-origin strain that began the metabolic research journey
02
OPTIMIZATION
C. lacerata - K1
Later reclassified as Ceriporia lamaritus, more stable and practical for scale-up.
03
ADVANCEMENT
Irpex lacteus f.k.
An EMS-derived strain whose mycelial culture was designated EFILA.
Controlled Production Flow
From staged culture to finished product formats.
A simplified view of how CL-K1® moves from starter culture through controlled cultivation, separation, concentration, sterilization, and final product format preparation.
Seed-culture
Production of the starter culture.
Pre-culture
Propagation of the starter culture.
Main-culture
Controlled culture stage for acquiring active ingredients.
Filtration
Separation of mycelium and culture broth.
RO Concentrate
Unheated reverse-osmosis concentration.
Sterilization
Controlled sterilization step before product format preparation.
Jelly products
Culture-derived application format.
Freeze-drying
Vacuum freeze-drying of the culture material.
Homogenization
Powdering and homogenization of dried cultures.
Tablet products
Dried culture-based application format.
Research Direction
Diabetes and Liver Metabolism
CL-K1® research focuses primarily on metabolic disorders, especially type 2 diabetes, impaired fasting glucose, insulin resistance, and liver-related metabolic dysfunction.
From a cellular perspective, these conditions are closely connected. Pancreatic beta-cell stress, impaired insulin signaling, liver glucose regulation, mitochondrial function, oxidative stress, and chronic inflammation all influence long-term metabolic balance.
CL-K1® is studied within this multi-target framework. Its research explores how fungal fermentation-derived bioactive compounds may support the cellular environment involved in glucose regulation, liver metabolism, energy production, and metabolic resilience
Further Applications
Skin Care Applications
Researchers have explored the skin care properties of CL-K1 cultures. Preliminary research suggests potential applications in improving skin hydration, supporting the skin barrier, and promoting skin renewal.
Our scientists have also contributed as inventors to earlier skin care patents. Related technologies have been incorporated into skin care products that have received positive consumer feedback.
Current Application & Future Potential
CL-K1® is currently commercialized through EFILA-related health supplement, medical nutrition, and metabolic health applications. This creates a practical and regulatory-compliant path for market entry while continuing to build clinical, functional, and mechanistic evidence.
Its deeper value lies in its research foundation: fungal strain development, fermentation technology, safety data, patented strain assets, regulatory recognition, and a clear focus on diabetes and liver-related metabolic health.
With continued evidence development, CL-K1® has the potential to grow from a standardized health ingredient into a supportive therapeutic ingredient platform and a future biopharmaceutical development candidate.